In patients with essential thrombocythemia or primary myelofibrosis, mutations in the Janus kinase 2 (JAK2) gene, mutations in exon 9 of the calreticulin gene, and activating mutations in the thrombopoietin receptor gene (MPL) are detected. Here, JAK2 is linked to primary myelofibrosis.